|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM199128286 |
| 003 |
DE-627 |
| 005 |
20231223214035.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.06.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0664.xml
|
| 035 |
|
|
|a (DE-627)NLM199128286
|
| 035 |
|
|
|a (NLM)20580618
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chéramy, Mikael
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.12.2010
|
| 500 |
|
|
|a Date Revised 20.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We have previously shown that two injections of 20 μg GAD-alum to recent onset type 1 diabetic children induced GADA levels in parallel to preservation of insulin secretion. Here we investigated if boosted GADA induced changes in IgG1, 2, 3 and 4 subclass distributions or affected GAD(65) enzyme activity. We further studied the specific effect of GAD-alum through analyses of IA-2A, tetanus toxoid and total IgE antibodies. Serum from children receiving GAD-alum or placebo was collected pre-treatment and after 3, 9, 15 and 21 months. At 3 months a reduced percentage of IgG1 and increased IgG3/IgG4 were detected in GAD-alum treated. Further, IA-2A, IgE and tetanus toxoid antibodies, as well as GAD(65) enzyme activity, were unaffected confirming the specific effect of treatment. In the GAD-alum group, higher pre-treatment GADA were associated to more pronounced C-peptide preservation. The induced IgG3/IgG4 and reduced IgG1 suggest a Th2 deviation of the immune response
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Alum Compounds
|2 NLM
|
| 650 |
|
7 |
|a Antibodies
|2 NLM
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a C-Peptide
|2 NLM
|
| 650 |
|
7 |
|a ICA512 autoantibody
|2 NLM
|
| 650 |
|
7 |
|a Immune Sera
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Tetanus Toxoid
|2 NLM
|
| 650 |
|
7 |
|a aluminum sulfate
|2 NLM
|
| 650 |
|
7 |
|a 34S289N54E
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin E
|2 NLM
|
| 650 |
|
7 |
|a 37341-29-0
|2 NLM
|
| 650 |
|
7 |
|a Glutamate Decarboxylase
|2 NLM
|
| 650 |
|
7 |
|a EC 4.1.1.15
|2 NLM
|
| 650 |
|
7 |
|a glutamate decarboxylase 2
|2 NLM
|
| 650 |
|
7 |
|a EC 4.1.1.15
|2 NLM
|
| 700 |
1 |
|
|a Skoglund, Camilla
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Johansson, Ingela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ludvigsson, Johnny
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hampe, Christiane S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Casas, Rosaura
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 137(2010), 1 vom: 15. Okt., Seite 31-40
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:137
|g year:2010
|g number:1
|g day:15
|g month:10
|g pages:31-40
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.06.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 137
|j 2010
|e 1
|b 15
|c 10
|h 31-40
|